ATE240345T1 - Eine neue kristalline polymorphe form von fluticasonepropionat, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon - Google Patents

Eine neue kristalline polymorphe form von fluticasonepropionat, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon

Info

Publication number
ATE240345T1
ATE240345T1 AT97909496T AT97909496T ATE240345T1 AT E240345 T1 ATE240345 T1 AT E240345T1 AT 97909496 T AT97909496 T AT 97909496T AT 97909496 T AT97909496 T AT 97909496T AT E240345 T1 ATE240345 T1 AT E240345T1
Authority
AT
Austria
Prior art keywords
fluticasonepropionate
production
pharmaceutical preparations
new crystalline
polymorphous form
Prior art date
Application number
AT97909496T
Other languages
English (en)
Inventor
Simon Murray Cooper
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE240345T1 publication Critical patent/ATE240345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Disintegrating Or Milling (AREA)
AT97909496T 1996-10-24 1997-10-23 Eine neue kristalline polymorphe form von fluticasonepropionat, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon ATE240345T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9622173.4A GB9622173D0 (en) 1996-10-24 1996-10-24 Particulate Products
PCT/GB1997/002929 WO1998017676A1 (en) 1996-10-24 1997-10-23 A novel polymorphic crystalline form of fluticasone propionate, a method for its production and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE240345T1 true ATE240345T1 (de) 2003-05-15

Family

ID=10801903

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909496T ATE240345T1 (de) 1996-10-24 1997-10-23 Eine neue kristalline polymorphe form von fluticasonepropionat, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon

Country Status (13)

Country Link
US (1) US6406718B1 (de)
EP (1) EP0937100B1 (de)
JP (1) JP2001502350A (de)
AT (1) ATE240345T1 (de)
AU (1) AU4717197A (de)
CA (1) CA2269134C (de)
DE (1) DE69722023T2 (de)
DK (1) DK0937100T3 (de)
ES (1) ES2198555T3 (de)
GB (1) GB9622173D0 (de)
PE (1) PE68099A1 (de)
PT (1) PT937100E (de)
WO (1) WO1998017676A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806462D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
GB9828204D0 (en) * 1998-12-21 1999-02-17 Smithkline Beecham Plc Process
HK1049621A1 (zh) 1999-06-09 2003-05-23 罗伯特‧E‧希弗斯 超临界流体辅助的喷雾和鼓泡乾燥
US20020133032A1 (en) * 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
EP2067784A3 (de) 2000-08-05 2012-08-22 Glaxo Group Limited 17.beta.-Carbothioat-17.alpha.-Arylcarbonyloxyloxy-Androstan-Derivate als entzündungshemmende Mittel
GB0021927D0 (en) * 2000-09-07 2000-10-25 Glaxo Group Ltd Use of pharmaceutical combination
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB0208742D0 (en) * 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
DE60211004T2 (de) * 2001-10-10 2006-08-31 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Pulververarbeitung mit unter druck stehenden gasförmigen fluids
GB0125604D0 (en) * 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
GB0202564D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
WO2004098561A2 (en) 2003-05-08 2004-11-18 Nektar Therapeutics Uk Ltd Particulate materials
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
EP1904219A4 (de) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Teilchenbildungsverfahren
EP2001439A2 (de) * 2006-03-07 2008-12-17 Novavax, Inc. Nanoemulsionen von schlecht löslichen pharmazeutischen aktivbestandteilen und herstellungsverfahren dafür
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
TW200817047A (en) * 2006-04-03 2008-04-16 Teva Pharma Drug microparticles
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
GB0702402D0 (en) 2007-02-08 2007-03-21 Thar Pharmaceuticals Inc Method of creating crystalline substances
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
JP2010111592A (ja) * 2008-11-04 2010-05-20 Aska Pharmaceutical Co Ltd プロピオン酸フルチカゾンを含む局所投与剤
WO2010138539A2 (en) 2009-05-27 2010-12-02 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
WO2013009591A1 (en) * 2011-07-08 2013-01-17 Pfizer Limited Process for the preparation of fluticasone propionate form 1
DK3181122T3 (da) * 2012-01-13 2023-06-06 Xspray Pharma Ab Publ Farmaceutisk dasatinib-sammensætning
CN107880091B (zh) 2012-05-08 2020-12-18 尼科斯眼药公司 疏水性治疗剂的制剂、其制备方法及应用
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN104004044A (zh) * 2013-02-25 2014-08-27 武汉诺安药业有限公司 高纯度丙酸氟替卡松制备方法
HRP20211271T1 (hr) 2014-08-18 2022-01-07 Alkermes Pharma Ireland Limited Pripravci aripiprazolskog predlijeka
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
CN108066329B (zh) * 2016-11-11 2021-11-16 江苏恒瑞医药股份有限公司 一种吸入用氟替卡松或其衍生物的微粒的制备方法
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE887518A (fr) * 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
GB2088877B (en) 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles

Also Published As

Publication number Publication date
US6406718B1 (en) 2002-06-18
DE69722023D1 (de) 2003-06-18
ES2198555T3 (es) 2004-02-01
AU4717197A (en) 1998-05-15
EP0937100A1 (de) 1999-08-25
EP0937100B1 (de) 2003-05-14
GB9622173D0 (en) 1996-12-18
DE69722023T2 (de) 2004-04-08
PT937100E (pt) 2003-09-30
CA2269134C (en) 2007-01-09
PE68099A1 (es) 1999-07-19
JP2001502350A (ja) 2001-02-20
WO1998017676A1 (en) 1998-04-30
CA2269134A1 (en) 1998-04-30
DK0937100T3 (da) 2003-09-01

Similar Documents

Publication Publication Date Title
DE69722023D1 (de) Eine neue kristalline polymorphe form von fluticasonepropionat, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon
DE122005000030I1 (de) Pregna-1, 4-dien-3, 20-dion-16-17-acetal-21-ester,Verfahren zur Herstellung, sowie diese enthaltendepharmazeutische Pr{parate.
EP0263569A3 (en) 9-alpha-hydroxysteroids,process for their preparation,process for the preparation of the corresponding 9(11)-dehydro-derivatives and pharmaceutical preparations containing said steroids
ATE231882T1 (de) 7alpha-(epsilon-aminoalkyl)-estratriene, verfahren zu deren herstellung, pharmazeutische präparate, die diese 7alpha-(epsilon-aminoalkyl)- estratriene enthalten sowie deren verwendung zur herstellung von arzneimitteln
ATE232543T1 (de) 11beta-halogen-7alpha-substituierte-estratriene verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha- substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
ATA293589A (de) Neue chinolinsulfonaminoderivate und verfahren zu deren herstellung sowie pharmazeutische zusammensetzung
FI970526L (fi) Estra-1,3,5(10)-trieenijohdannaiset, niiden valmistusmenetelmät sekä näitä yhdisteitä sisältävät farmaseuttiset koostumukset
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
ATA900894A (de) Pharmazeutische kompositionen zum vorbeugen und heilen von krebserkrankungen und verfahren zu ihrer herstellung
CA2166332A1 (en) Antiglucocorticoid steroids for the treatment of anxiety disorders
ATA87388A (de) Neue purinylribofuranuronsaeurederivate, verfahren zu deren herstellung und sie enthaltende therapeutische praeparate
DE3787437D1 (de) Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.
DE69719930D1 (de) Verfahren zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung, und Vorrichtung dafür
DE68903059D1 (de) Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten.
FI951759A7 (fi) Menetelmä 2,2-difluoriketeenisilyyli-O,S-asetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihapon O,S-estereiden valmistamiseksi
DE69514724D1 (de) Verfahren zur Herstellung von 20-oxo, 17-alpha, 21-dihydroxy Steroidederivate und neue Zwischenprodukte dafür
FI952203L (fi) Sykloheksaanijohdannaiset, menetelmä niiden valmistamiseksi ja yhdisteiden käyttö sairauksien hoitamiseksi
DE59505276D1 (de) Verfahren zur Herstellung von 2-Chlor-6-nitrophenyl-alkylsulfanen und neue 2-Chlor-6-nitrophenyl-alkyl-sulfane
DE59505070D1 (de) Verfahren zur Herstellung von aliphatischen und cycloaliphatischen Oximen
DE69321785D1 (de) Neues Verfahren zur Herstellung von 20-keto 21(S)-hydroxy-Steroiden und Zwischenprodukten davon
ATE157670T1 (de) Digitoxigenin und dihydrodigitoxigenin 3-beta- derivate und pharmazeutische präparate davon, zur behandlung von hypertonie
ATA234589A (de) Neue 2-methoxycarbonyl substituierte n,n'-di(trimethoxybenzoyl)piperazine, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE59305709D1 (de) Verfahren zur Herstellung von 1,4-Diaminoanthrachinon-2,3-disulfonsäure und 1,4-Diaminoanthrachinon-2,3-dinitril
AU1167097A (en) 18-methyl 16-methylene 19-nor pregnane derivatives as progestins, pharmaceutical compositions containing them and process for the preparation thereof
HUT72467A (en) 17alpha and 17beta-substituted estra-1,3,5(10)-triene-3-carboxylic acids, pharmaceutical compositions containing them, intermediates and process for their production

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0937100

Country of ref document: EP

EELV Lapsed due to withdrawal
REZ Deleted due to withdrawal